Collectively, these results indicate that, although STAG2 knockdown activates ERK signaling in both BRAF-mutant thyroid cancer cells and melanoma cells, it causes distinct cellular response to MEK inhibitor. This evidence concerns the gene STAG2 and thyroid gland carcinoma.